These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21791006)

  • 1. The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation.
    Jannini EA; McMahon C; Chen J; Aversa A; Perelman M
    J Sex Med; 2011 Aug; 8(8):2135-43. PubMed ID: 21791006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review.
    McMahon CG; McMahon CN; Leow LJ; Winestock CG
    BJU Int; 2006 Aug; 98(2):259-72. PubMed ID: 16879663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions.
    Jannini EA; Isidori AM; Aversa A; Lenzi A; Althof SE
    J Sex Med; 2013 Oct; 10(10):2359-69. PubMed ID: 24112352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?
    Aversa A; Francomano D; Bruzziches R; Natali M; Spera G; Lenzi A
    Int J Impot Res; 2011; 23(1):17-23. PubMed ID: 21270821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of pharmacotherapy in premature ejaculation.
    Porst H
    J Sex Med; 2011 Oct; 8 Suppl 4():335-41. PubMed ID: 21967395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
    Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
    BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
    Jannini EA; DeRogatis LR; Chung E; Brock GB
    J Sex Med; 2012 Jan; 9(1):26-33. PubMed ID: 22221307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data.
    Chen J; Keren-Paz G; Bar-Yosef Y; Matzkin H
    Eur Urol; 2007 Nov; 52(5):1331-9. PubMed ID: 17728050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current therapeutic strategies for premature ejaculation and future perspectives.
    Xin ZC; Zhu YC; Yuan YM; Cui WS; Jin Z; Li WR; Liu T
    Asian J Androl; 2011 Jul; 13(4):550-7. PubMed ID: 21532601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective evaluation of the efficacy of daily paroxetine/tadalafil combination in patients with premature ejaculation and erectile dysfunction.
    Onal B; Can O; Ermec B; Culha MG
    Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4248-4253. PubMed ID: 37203851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future pharmacotherapies of premature ejaculation.
    Hellstrom WJ
    J Sex Med; 2006 Sep; 3 Suppl 4():332-41. PubMed ID: 16939478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phosphodiesterase type 5 inhibitors for premature ejaculation: advances in studies].
    Mo DS; Shang XJ; Huang YF
    Zhonghua Nan Ke Xue; 2015 Jun; 21(6):561-5. PubMed ID: 26242050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Premature ejaculation].
    Wespes E; Roumeguère T
    Rev Med Brux; 2007 Sep; 28(4):374-7. PubMed ID: 17958036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Treatment for Premature Ejaculation in the Light of Currently Used Therapies: A Review.
    Porst H; Burri A
    Sex Med Rev; 2019 Jan; 7(1):129-140. PubMed ID: 30057136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories.
    Abdel-Hamid IA; Andersson KE; Salonia A
    Expert Opin Ther Targets; 2011 Mar; 15(3):325-40. PubMed ID: 21204729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation.
    Wang WF; Minhas S; Ralph DJ
    Int J Androl; 2006 Oct; 29(5):503-09. PubMed ID: 16573707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of sildenafil in the treatment of premature ejaculation complicated by erectile dysfunction].
    Li X; Zhang SX; Cheng HM; Zhang WD
    Zhonghua Nan Ke Xue; 2003; 9(4):266-9. PubMed ID: 12931367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil.
    Paduch DA; Bolyakov A; Beardsworth A; Watts SD
    BJU Int; 2012 Apr; 109(7):1060-7. PubMed ID: 21883853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.